MedTrace Logo

Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain

NCT01433328 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2023-02-01

No results posted yet for this study

Summary

Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients. The investigators plan to treat patients receiving treprostinil with a subcutaneous infusion of lidocaine (a local anesthestic) to treat the pain.

Conditions

Interventions

DRUG

Lidocaine

Lidocaine

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Jewish General Hospital

    lead OTHER

Principal Investigators

  • David Langleben, MD · Chair, Cardiology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-03-31
Completion
2012-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433328 on ClinicalTrials.gov